Skip to main content
Erschienen in: Osteoporosis International 1/2011

01.01.2011 | Original Article

An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis

verfasst von: L. Caplan, A. E. Hines, E. Williams, A. V. Prochazka, K. G. Saag, F. Cunningham, E. Hutt

Erschienen in: Osteoporosis International | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Summary

We applied regression techniques to a large cohort of patients to understand why certain patients are prescribed medications to prevent glucocorticoid-induced osteoporosis (GIO). Rates of prescriptions to prevent osteoporosis were low. The presence of drugs and disorders associated with osteoporosis and gastrointestinal conditions actually are associated with a decreased likelihood of receiving osteoporosis-preventing medications.

Introduction

To understand why some patients are prescribed medications to prevent GIO while other patients are not, we examined whether there is an association among osteoporosis-inducing medical conditions or medications and prescriptions for osteoporosis prophylaxis in a large cohort of rheumatoid arthritis patients on chronic glucocorticoids.

Methods

Department of Veterans’ Affairs national administrative databases were used to construct a cohort (n = 9,605) and provide the data for this study. Multivariate logistic regression was performed to determine medical conditions and medications associated with dispensing of GIO-preventive medications, controlling for sociodemographic variables, comorbidities, glucocorticoid dosage, prior fractures, and rheumatoid arthritis severity. A subanalysis examined predictors of early GIO prevention.

Results

Subjects were more likely to receive GIO prophylaxis if they were older, African American, treated with multiple antirheumatic disease-modifying drugs, or received greater glucocorticoid exposure. The prescription of certain drug classes (loop diuretics and anticonvulsants) and conditions (malignancy, renal insufficiency, alcohol abuse, and hepatic disease) were associated with lower likelihood of GIO prophylaxis, despite putative links between these agents/conditions and osteoporosis. The presence of gastrointestinal disorders dramatically decreased likelihood of GIO prophylaxis. Few characteristics predicted the dispensing of GIO-preventing medications within 7 days of the initial glucocorticoid start date.

Conclusions

Rates of prescriptions to prevent osteoporosis in a cohort of older men with rheumatoid arthritis on chronic glucocorticoids were low. Gastrointestinal disorders and drugs and disorders potentially linked to osteoporosis are associated with diminished odds of being prescribed GIO-preventing medications.
Literatur
1.
2.
Zurück zum Zitat Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93:105–111CrossRefPubMed Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93:105–111CrossRefPubMed
3.
Zurück zum Zitat Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000CrossRefPubMed Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000CrossRefPubMed
4.
Zurück zum Zitat American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRef American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRef
5.
Zurück zum Zitat Adler RA, Hochberg MC (2003) Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163:2619–2624CrossRefPubMed Adler RA, Hochberg MC (2003) Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163:2619–2624CrossRefPubMed
6.
Zurück zum Zitat Compston JE (2007) Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 9:78–84CrossRefPubMed Compston JE (2007) Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 9:78–84CrossRefPubMed
7.
Zurück zum Zitat Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000) Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 29:228–251CrossRefPubMed Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000) Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 29:228–251CrossRefPubMed
8.
Zurück zum Zitat Sambrook PN, Diamond T, Ferris L, Fiatarone-Singh M, Flicker L, MacLennan A, Nowson C, O’Neill S, Greville H (2001) Corticosteroid induced osteoporosis. Guidelines for treatment. Aust Fam Physician 30:793–796PubMed Sambrook PN, Diamond T, Ferris L, Fiatarone-Singh M, Flicker L, MacLennan A, Nowson C, O’Neill S, Greville H (2001) Corticosteroid induced osteoporosis. Guidelines for treatment. Aust Fam Physician 30:793–796PubMed
9.
Zurück zum Zitat Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109CrossRefPubMed Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109CrossRefPubMed
10.
Zurück zum Zitat Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8–19CrossRefPubMed Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8–19CrossRefPubMed
11.
Zurück zum Zitat Geusens PP, Lems WF, Verhaar HJ, Leusink G, Goemaere S, Zmierczack H, Compston J (2006) Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 12:539–548CrossRefPubMed Geusens PP, Lems WF, Verhaar HJ, Leusink G, Goemaere S, Zmierczack H, Compston J (2006) Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 12:539–548CrossRefPubMed
12.
Zurück zum Zitat Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 7:597–605PubMed Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 7:597–605PubMed
13.
Zurück zum Zitat Buckley LM, Marquez M, Hudson JO, Downs RW, Vacek P, Small RE, Poses R (1998) Variations in physicians’ judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 25:2195–2202PubMed Buckley LM, Marquez M, Hudson JO, Downs RW, Vacek P, Small RE, Poses R (1998) Variations in physicians’ judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 25:2195–2202PubMed
14.
Zurück zum Zitat Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL (2006) Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 33:1651–1657PubMed Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL (2006) Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 33:1651–1657PubMed
15.
Zurück zum Zitat Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142CrossRefPubMed Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142CrossRefPubMed
16.
Zurück zum Zitat Elliott ME, Farrah RM, Binkley NC, Carnes ML, Gudmundsson A (2000) Management of glucocorticoid-induced osteoporosis in male veterans. Ann Pharmacother 34:1380–1384PubMed Elliott ME, Farrah RM, Binkley NC, Carnes ML, Gudmundsson A (2000) Management of glucocorticoid-induced osteoporosis in male veterans. Ann Pharmacother 34:1380–1384PubMed
17.
Zurück zum Zitat Feldstein AC, Elmer PJ, Nichols GA, Herson M (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16:2168–2174CrossRefPubMed Feldstein AC, Elmer PJ, Nichols GA, Herson M (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16:2168–2174CrossRefPubMed
18.
Zurück zum Zitat Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51:383–387CrossRefPubMed Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51:383–387CrossRefPubMed
19.
Zurück zum Zitat Curtis JR, Westfall AO, Allison J, Becker A, Melton ME, Freeman A, Kiefe CI, MacArthur M, Ockershausen T, Stewart E, Weissman N, Saag KG (2007) Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med 167:591–596CrossRefPubMed Curtis JR, Westfall AO, Allison J, Becker A, Melton ME, Freeman A, Kiefe CI, MacArthur M, Ockershausen T, Stewart E, Weissman N, Saag KG (2007) Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med 167:591–596CrossRefPubMed
20.
Zurück zum Zitat Chitre MM, Hayes W (2008) 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan. J Manag Care Pharm 14:281–290PubMed Chitre MM, Hayes W (2008) 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan. J Manag Care Pharm 14:281–290PubMed
21.
Zurück zum Zitat Aagaard EM, Lin P, Modin GW, Lane NE (1999) Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 107:456–460CrossRefPubMed Aagaard EM, Lin P, Modin GW, Lane NE (1999) Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 107:456–460CrossRefPubMed
22.
Zurück zum Zitat Mudano A, Allison J, Hill J, Rothermel T, Saag K (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28:1298–1305PubMed Mudano A, Allison J, Hill J, Rothermel T, Saag K (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28:1298–1305PubMed
23.
Zurück zum Zitat Duyvendak M, Naunton M, Atthobari J, van den Berg PB, Brouwers JR (2007) Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005. Osteoporos Int 18:1429–1433CrossRefPubMed Duyvendak M, Naunton M, Atthobari J, van den Berg PB, Brouwers JR (2007) Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005. Osteoporos Int 18:1429–1433CrossRefPubMed
24.
Zurück zum Zitat Singh JA, Holmgren AR, Noorbaloochi S (2004) Accuracy of veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 51:952–957CrossRefPubMed Singh JA, Holmgren AR, Noorbaloochi S (2004) Accuracy of veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 51:952–957CrossRefPubMed
25.
Zurück zum Zitat Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17:1268–1274CrossRefPubMed Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17:1268–1274CrossRefPubMed
26.
Zurück zum Zitat Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMed Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMed
27.
Zurück zum Zitat Shekelle P, Munjas B, Liu H, Paige N, Zhou A (2007) Screening men for osteoporosis: who & how. Department of Veterans Affairs (HSR&D Evidence Synthesis Pilot Program), Washington, DC Shekelle P, Munjas B, Liu H, Paige N, Zhou A (2007) Screening men for osteoporosis: who & how. Department of Veterans Affairs (HSR&D Evidence Synthesis Pilot Program), Washington, DC
28.
Zurück zum Zitat Chrousos GP (2001) Glucocorticoid therapy. In: Felig P, Frohman L (eds) Endocrinology and metabolism, 4th edn, Chap 14. McGraw-Hill, New York, pp 609–632 Chrousos GP (2001) Glucocorticoid therapy. In: Felig P, Frohman L (eds) Endocrinology and metabolism, 4th edn, Chap 14. McGraw-Hill, New York, pp 609–632
29.
Zurück zum Zitat Mikuls TR, Saag KG, George V, Mudano AS, Banerjee S (2005) Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. J Rheumatol 32:870–875PubMed Mikuls TR, Saag KG, George V, Mudano AS, Banerjee S (2005) Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. J Rheumatol 32:870–875PubMed
30.
Zurück zum Zitat Cruse LM, Valeriano J, Vasey FB, Carter JD (2006) Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 12:221–225CrossRefPubMed Cruse LM, Valeriano J, Vasey FB, Carter JD (2006) Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 12:221–225CrossRefPubMed
31.
Zurück zum Zitat Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154:854–864CrossRefPubMed Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154:854–864CrossRefPubMed
32.
Zurück zum Zitat Schneeweiss S, Wang PS, Avorn J, Glynn RJ (2003) Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 38:1103–1120CrossRefPubMed Schneeweiss S, Wang PS, Avorn J, Glynn RJ (2003) Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 38:1103–1120CrossRefPubMed
33.
Zurück zum Zitat Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778CrossRefPubMed Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778CrossRefPubMed
34.
Zurück zum Zitat Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P (2000) Predictors of fractures in elderly women. Osteoporos Int 11:134–140CrossRefPubMed Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P (2000) Predictors of fractures in elderly women. Osteoporos Int 11:134–140CrossRefPubMed
35.
Zurück zum Zitat Petty SJ, O’Brien TJ, Wark JD (2007) Anti-epileptic medication and bone health. Osteoporos Int 18:129–142CrossRefPubMed Petty SJ, O’Brien TJ, Wark JD (2007) Anti-epileptic medication and bone health. Osteoporos Int 18:129–142CrossRefPubMed
36.
Zurück zum Zitat Sheppard MC, Holder R, Franklyn JA (2002) Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 162:338–343CrossRefPubMed Sheppard MC, Holder R, Franklyn JA (2002) Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 162:338–343CrossRefPubMed
37.
Zurück zum Zitat Mezuk B, Eaton WW, Golden SH (2008) Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int 19:1–12CrossRefPubMed Mezuk B, Eaton WW, Golden SH (2008) Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int 19:1–12CrossRefPubMed
38.
Zurück zum Zitat Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos Int 18:427–444CrossRefPubMed Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos Int 18:427–444CrossRefPubMed
39.
Zurück zum Zitat Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465–5476CrossRefPubMed Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465–5476CrossRefPubMed
40.
Zurück zum Zitat Melton LJ III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV (2005) Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20:487–493CrossRefPubMed Melton LJ III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV (2005) Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20:487–493CrossRefPubMed
41.
Zurück zum Zitat Berg KM, Kunins HV, Jackson JL, Nahvi S, Chaudhry A, Harris KA Jr, Malik R, Arnsten JH (2008) Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 121:406–418CrossRefPubMed Berg KM, Kunins HV, Jackson JL, Nahvi S, Chaudhry A, Harris KA Jr, Malik R, Arnsten JH (2008) Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 121:406–418CrossRefPubMed
42.
Zurück zum Zitat Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566–571CrossRefPubMed Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566–571CrossRefPubMed
43.
Zurück zum Zitat Gal-Moscovici A, Sprague SM (2007) Osteoporosis and chronic kidney disease. Semin Dial 20:423–430CrossRefPubMed Gal-Moscovici A, Sprague SM (2007) Osteoporosis and chronic kidney disease. Semin Dial 20:423–430CrossRefPubMed
44.
Zurück zum Zitat Trautwein C, Possienke M, Schlitt HJ, Boker KH, Horn R, Raab R, Manns MP, Brabant G (2000) Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 95:2343–2351CrossRefPubMed Trautwein C, Possienke M, Schlitt HJ, Boker KH, Horn R, Raab R, Manns MP, Brabant G (2000) Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 95:2343–2351CrossRefPubMed
45.
Zurück zum Zitat Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El MA (2008) Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 26:379–384CrossRefPubMed Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El MA (2008) Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 26:379–384CrossRefPubMed
46.
Zurück zum Zitat Perreault S, Dragomir A, Desgagne A, Blais L, Rossignol M, Blouin J, Moride Y, Ste-Marie LG, Fernandes JC (2005) Trends and determinants of antiresorptive drug use for osteoporosis among elderly women. Pharmacoepidemiol Drug Saf 14:685–695CrossRefPubMed Perreault S, Dragomir A, Desgagne A, Blais L, Rossignol M, Blouin J, Moride Y, Ste-Marie LG, Fernandes JC (2005) Trends and determinants of antiresorptive drug use for osteoporosis among elderly women. Pharmacoepidemiol Drug Saf 14:685–695CrossRefPubMed
47.
Zurück zum Zitat Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458–1465CrossRefPubMed Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458–1465CrossRefPubMed
48.
Zurück zum Zitat Alexopoulou A, Dourakis SP, Mantzoukis D, Pitsariotis T, Kandyli A, Deutsch M, Archimandritis AJ (2008) Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med 19:505–510CrossRefPubMed Alexopoulou A, Dourakis SP, Mantzoukis D, Pitsariotis T, Kandyli A, Deutsch M, Archimandritis AJ (2008) Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med 19:505–510CrossRefPubMed
49.
Zurück zum Zitat Liao HL, Chen JT, Ma TC, Chang YS (2008) Analysis of drug-drug interactions (DDIs) in nursing homes in Central Taiwan. Arch Gerontol Geriatr 47:99–107CrossRefPubMed Liao HL, Chen JT, Ma TC, Chang YS (2008) Analysis of drug-drug interactions (DDIs) in nursing homes in Central Taiwan. Arch Gerontol Geriatr 47:99–107CrossRefPubMed
50.
Zurück zum Zitat Perkins AJ, Kroenke K, Unutzer J, Katon W, Williams JW, Hope C, Callahan CM (2004) Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol 57:1040–1048CrossRefPubMed Perkins AJ, Kroenke K, Unutzer J, Katon W, Williams JW, Hope C, Callahan CM (2004) Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol 57:1040–1048CrossRefPubMed
51.
Zurück zum Zitat Lurk JT, DeJong DJ, Woods TM, Knell ME, Carroll CA (2004) Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. Am J Health Syst Pharm 61:267–272PubMed Lurk JT, DeJong DJ, Woods TM, Knell ME, Carroll CA (2004) Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. Am J Health Syst Pharm 61:267–272PubMed
52.
Zurück zum Zitat Li X, Guh D, Lacaille D, Esdaile J, Anis AH (2007) The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities. Health Policy 82:340–347CrossRefPubMed Li X, Guh D, Lacaille D, Esdaile J, Anis AH (2007) The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities. Health Policy 82:340–347CrossRefPubMed
Metadaten
Titel
An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis
verfasst von
L. Caplan
A. E. Hines
E. Williams
A. V. Prochazka
K. G. Saag
F. Cunningham
E. Hutt
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 1/2011
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1201-x

Weitere Artikel der Ausgabe 1/2011

Osteoporosis International 1/2011 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.